DISCOUNT-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 07:45:58 2024-06-17 EDT | ||
| 0.1 EUR | -16.67% |
|
| 3 months | -50.00% | ||
| 6 months | -57.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 0.1 | -16.67% |
| 24-06-14 | 0.12 | 0.00% |
| 24-06-13 | 0.12 | 0.00% |
| 24-06-12 | 0.12 | 0.00% |
| 24-06-11 | 0.12 | +9.09% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 07:45 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC7V8Q |
| ISIN | DE000HC7V8Q2 |
| Date issued | 2023-07-04 |
| Strike | 200 $ |
| Maturity | 2024-12-18 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 0.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.68 € |
|---|---|
| Lowest since issue | 0.072 € |
| Spread | 0.04 € |
| Spread % | 28.57% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6
USD
Average target price
316.4
USD
Spread / Average Target
+5.97%
- Stock Market
- Certificates
- Certificat
